Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;6(12):657-66.
doi: 10.1038/nrneurol.2010.160. Epub 2010 Nov 9.

Chemotherapy-induced peripheral neurotoxicity

Affiliations
Review

Chemotherapy-induced peripheral neurotoxicity

Guido Cavaletti et al. Nat Rev Neurol. 2010 Dec.

Abstract

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common, potentially severe and dose-limiting adverse effect of cancer treatment; however, the effects of CIPN on the daily life of individuals are not completely understood. CIPN can be induced by several types of drugs that are widely used in the treatment of solid and hematological malignancies. Our knowledge of the mechanisms underlying CIPN is incomplete, but structural properties of the various neurotoxic compounds might contribute to variations in the pathogenetic mechanisms of damage, in addition to the type of neurotoxicity, severity of the clinical condition, and incidence of CIPN. No drugs capable of preventing the occurrence of CIPN or ameliorating its long-term course are available, and chemotherapy schedule modification is often required to limit its severity, which could potentially prevent patients from receiving the most effective treatment for cancer. Moreover, symptomatic therapy is often largely ineffective in reducing CIPN symptoms. In this Review, the mechanistic and clinical aspects of this unpredictable condition are considered, along with the controversial aspects of CIPN, including the onset mechanisms associated with the different drug types, assessment of the patient's condition, and the current status of neuroprotection and treatment options.

PubMed Disclaimer

References

    1. J Clin Invest. 1998 Jun 15;101(12):2842-50 - PubMed
    1. J Peripher Nerv Syst. 2006 Jun;11(2):135-41 - PubMed
    1. Muscle Nerve. 2001 Aug;24(8):1034-9 - PubMed
    1. Neurotoxicology. 1997;18(1):137-45 - PubMed
    1. Eur J Cancer. 2005 Jul;41(10):1460-6 - PubMed

MeSH terms

Substances